Enovis (NYSE:ENOV – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of $0.92 per share and revenue of $555.14 million for the quarter. Parties interested in listening to the company’s conference call can do so using this link.
Enovis Price Performance
Shares of NYSE:ENOV opened at $43.55 on Tuesday. The firm has a market cap of $2.48 billion, a price-to-earnings ratio of -19.88 and a beta of 1.94. The firm has a fifty day moving average price of $45.03 and a 200 day moving average price of $44.38. Enovis has a fifty-two week low of $38.27 and a fifty-two week high of $63.96. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27.
Wall Street Analysts Forecast Growth
Separately, Needham & Company LLC reiterated a “buy” rating and issued a $65.00 price target on shares of Enovis in a research note on Thursday, November 7th.
Enovis Company Profile
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
Read More
- Five stocks we like better than Enovis
- The 3 Best Retail Stocks to Shop for in August
- Finding Hidden Gems: Unconventional Penny Stock Investing
- 3 Healthcare Dividend Stocks to Buy
- Price Targets on NVIDIA Rise in Front of Earnings
- What Are Growth Stocks and Investing in Them
- Archer Aviation Stock Skids: Mistaking Progress for Bad News?
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
